Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Motzer et al. (Sat,) studied this question.

www.synapsesocial.com/papers/69d7c01a3b601d7be3ae2ae9 — DOI: https://doi.org/10.1056/nejmoa2035716

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma· 2020 · 134 citations
2. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial· 2020 · 116 citations
3. Karnofsky performance status revisited: reliability, validity, and guidelines.· 1984 · 1,501 citations
4. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma· 2002 · 1,502 citations
5. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)· 2013 · 87 citations